PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 38 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $658,000 | -2.8% | 76,640 | +135.6% | 0.00% | – |
| Q4 2017 | $677,000 | +63.1% | 32,534 | +38.4% | 0.00% | – |
| Q3 2017 | $415,000 | +57.2% | 23,508 | +0.6% | 0.00% | – |
| Q2 2017 | $264,000 | +5.2% | 23,372 | +19.5% | 0.00% | – |
| Q1 2017 | $251,000 | -50.2% | 19,560 | -14.7% | 0.00% | – |
| Q4 2016 | $504,000 | +136.6% | 22,918 | +127.1% | 0.00% | – |
| Q3 2016 | $213,000 | – | 10,093 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |